21482699|novel|C0205314^C0679622|start=2|end=7|CONC
21482699|vascular|C1801960^C0005847|start=27|end=35|CONC^ANAT
21482699|normalization therapy|C0556530|start=36|end=57|PROC
21482699|targeted|C0599894^C1521840|start=58|end=66|PHYS^CONC
21482699|cd160|C1424685|start=81|end=86|GENE
21482699|angiogenesis|C0302600^C1519670|start=97|end=109|DISO^PHYS
21482699|plays|C0032214|start=110|end=115|ACTI
21482699|essential|C0205224|start=119|end=128|CONC
21482699|role|C1705809^C0035820^C1705812^C1704326^C1705811^C1705810|start=129|end=133|ACTI^CONC
21482699|diseases of the eye|C0015397|start=145|end=164|DISO
21482699|growth|C2911660^C0220844^C0018270^C1621966|start=176|end=182|PHYS^ACTI
21482699|solid tumors|C0280100|start=186|end=198|DISO
21482699|therapies|C0087111|start=228|end=237|PROC
21482699|limited|C0439801^C3542948|start=243|end=250|CONC
21482699|benefits|C0814225|start=251|end=259|CONC
21482699|cases|C1533148^C0868928|start=271|end=276|CONC
21482699|report|C0684224^C3273238^C0700287|start=281|end=287|PROC^CONC
21482699|effects|C1280500|start=307|end=314|CONC
21482699|antibody|C1621287^C3665580|start=331|end=339|PHYS^ANAT
21482699|cl1|C1413927|start=341|end=344|GENE
21482699|models|C0026336^C3161035|start=367|end=373|DEVI^CONC
21482699|neovascularization|C0027686|start=377|end=395|DISO
21482699|cl1|C1413927|start=397|end=400|GENE
21482699|cd160|C1424685|start=421|end=426|GENE
21482699|membrane|C0596901^C1706182^C0025255|start=430|end=438|OBJC^ANAT
21482699|species|C1548151^C3272777^C2698635^C1705920|start=485|end=492|PHYS^CONC
21482699|show|C1547282|start=497|end=501|CONC
21482699|cd160|C1424685|start=507|end=512|GENE
21482699|expressed|C1515670^C1171362^C0017262|start=516|end=525|PHYS
21482699|endothelial cells|C0225336|start=533|end=550|ANAT
21482699|newly|C0750546|start=554|end=559|CONC
21482699|formed|C0205431|start=560|end=566|CONC
21482699|blood vessels|C0005847|start=567|end=580|ANAT
21482699|colon carcinoma|C0699790|start=590|end=605|DISO
21482699|b16 melanoma|C0004565|start=616|end=628|DISO
21482699|vessels|C0005847|start=640|end=647|ANAT
21482699|tissues|C0040300|start=659|end=666|ANAT
21482699|cl1|C1413927|start=668|end=671|GENE
21482699|reduced|C0392756|start=675|end=682|CONC
21482699|fibroblast growth factor 2|C0919506|start=683|end=709|GENE
21482699|induced|C0205263|start=710|end=717|CONC
21482699|neovascularization|C0027686|start=718|end=736|DISO
21482699|rabbit|C3853317|start=744|end=750|OBJC
21482699|cornea|C1550625^C0010031^C1278889|start=751|end=757|ANAT
21482699|mouse model|C2986594|start=764|end=775|DISO
21482699|oxygen|C2359957^C1547125|start=779|end=785|PHYS^CONC
21482699|induced|C0205263|start=786|end=793|CONC
21482699|retinopathy|C0035309|start=794|end=805|DISO
21482699|plug|C1705909^C0182324|start=831|end=835|OBJC^DEVI
21482699|assay|C0243073^C1510438^C0005507|start=836|end=841|PROC^CONC
21482699|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=843|end=852|PROC^CONC
21482699|b16 melanoma|C0004565|start=856|end=868|DISO
21482699|bearing|C1704689|start=869|end=876|DEVI
21482699|mice|C1413131^C1417166|start=877|end=881|GENE
21482699|cl1|C1413927|start=887|end=890|GENE
21482699|combined|C0205195|start=894|end=902|CONC
21482699|chemotherapy|C0392920^C3665472^C0013217|start=925|end=937|PROC^CONC
21482699|regression|C0684321^C0684320|start=945|end=955|DISO^PHYS
21482699|tumor vasculature|C1658953|start=963|end=980|DISO
21482699|normalization|C1882115|start=985|end=998|PROC
21482699|remaining|C1527428|start=1006|end=1015|CONC
21482699|vessels|C0005847|start=1016|end=1023|ANAT
21482699|doppler ultrasonography|C0242837|start=1036|end=1059|PROC
21482699|intravital microscopy|C0596795|start=1061|end=1082|PROC
21482699|histology|C1552405^C0344441^C0019638^C0205462^C1608506|start=1088|end=1097|OCCU^PROC^CONC
21482699|studies|C0947630|start=1105|end=1112|PROC
21482699|cd160|C1424685|start=1122|end=1127|GENE
21482699|potential|C3245505|start=1133|end=1142|CONC
21482699|new|C0205314^C1553390^C2986548^C1578513|start=1143|end=1146|PROC^CONC
21482699|target|C1521840^C2986546|start=1147|end=1153|PROC^CONC
21482699|cases|C1533148^C0868928|start=1157|end=1162|CONC
21482699|pathological|C0030664^C1521733|start=1172|end=1184|OCCU^CONC
21482699|ocular|C0042789^C0015392^C1299003|start=1185|end=1191|PHYS^ANAT^CONC
21482699|tumor|C0027651^C1578706|start=1196|end=1201|DISO^CONC
21482699|neoangiogenesis|C0027686|start=1202|end=1217|DISO
21482699|resistant to|C0332325|start=1248|end=1260|CONC
21482699|drugs|C3687832|start=1285|end=1290|PROC
